Erika Hamilton, MD, from Sarah Cannon Research Institute in Nashville, TN, discusses the Phase Ib trial (NCT04072952) of vepdegestrant in combination with palbociclib for heavily pretreated patients with ER-positive metastatic breast cancer. Among the 46 patients treated, two-thirds had ESR1 mutations at baseline. The combination showed successful activity with a clinical benefit rate of 63% and an overall response rate of 42%. Notably, the duration of response was 10.2 months, and the progression-free survival (PFS) was 11.1 months, with no significant difference based on the presence of baseline ESR1 mutations. This promising outcome suggests potential efficacy in patients with endocrine resistance. This interview took place at the 2024 ASCO Gastrointestinal (GI) Cancers Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.